VirTrial
APRIL 18, 2024
Study data is always subject to scrutiny by regulators, which further highlights its importance. Given the industry is a highly regulated one, there are always new regulations being issued. Given these regulations are not new, it is strange that industry has not prompted a complete solution to this already.
XTalks
APRIL 6, 2023
Modern software development concepts from ecommerce applications are helping eClinical applications meet the precise needs of each clinical trial. IRT solutions help clinical trial sponsors meet the complexities of patient randomization and clinical supply management. How is Modern Software Impacting IRT Platforms?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 10, 2021
About MorphoSys MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for patients suffering from cancer and autoimmune diseases. In 2017, Tremfya (R) , developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc.,
Pharmaceutical Technology
MAY 24, 2023
Every major pharma company is now involved in CGT development which has resulted in the approval of 28 therapies by the FDA thereby making CGT no longer a niche category of therapies. Allogeneic therapies begin with healthy donor samples to develop the eventual therapeutic product which can be administered to multiple patients.
The Pharma Data
JANUARY 24, 2021
Management of the Company believe that the proposed acquisition will strengthen PharmaDrug’s product pipeline, intellectual property portfolio and pharmaceutical development expertise. Research and development efforts will be led by Dr. Paul Van Slyke. . – January 25, 2021) – PharmaDrug Inc. About PharmaDrug Inc.
Drug Discovery World
MARCH 13, 2023
While there is no silver bullet for increasing the availability of CGTs, improving manufacturing processes that enable their development at scale can help reduce the cost of these treatments and get them to those who need them most. But now, the increased efficiency is likely making drug development cheaper.
Drug Discovery World
NOVEMBER 3, 2022
Paul Viggers , Chief Commercial Officer at TrakCel, explains how it fits into the drug discovery and development sector. . 1 Emily was a seven-year-old girl who relapsed a second time following two years battling leukaemia, out of standard treatment options, and her life was saved by a CAR-T treatment in early clinical trial.
Expert insights. Personalized for you.
59 
Let's personalize your content